Current Status and Perspective of Immunotherapy in Gastrointestinal Cancers

Overview

Journal J Cancer

Specialty Oncology

Date 2016 Oct 5

PMID 27698896

Citations 5

Authors

Jung Hoon Kim

Bum Jun Kim

Hyeong Su Kim

Jung Han Kim

Affiliations

Soon will be listed here.

Abstract

Cancer immunotherapy is at dawn of the Renaissance after the Medieval Dark Ages. Recent advances of understanding tumor immunology and molecular drug development are leading us to the epoch of cancer immunotherapy. Some types of immunotherapy have shown to provide survival benefit for patients with solid tumors such as malignant melanoma, renal cell carcinoma, or non-small cell lung cancer. Several studies have suggested that immune checkpoint inhibition might be effective in some patients with gastrointestinal cancers. However, the era of cancer immunotherapy in gastrointestinal cancers is still in an inchoate stage. Here we briefly review the current status and perspective of immunotherapeutic approaches in patients with gastrointestinal cancers.

Citing Articles

The Effects of CD73 on Gastrointestinal Cancer Progression and Treatment.

Sun P, Zheng X, Li X J Oncol. 2022; 2022:4330329.

PMID: 35620732 PMC: 9130010. DOI: 10.1155/2022/4330329.

The role of myeloid-derived suppressor cells in gastrointestinal cancer.

Cui C, Lan P, Fu L Cancer Commun (Lond). 2021; 41(6):442-471.

PMID: 33773092 PMC: 8211353. DOI: 10.1002/cac2.12156.

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.

Long J, Lin J, Wang A, Wu L, Zheng Y, Yang X J Hematol Oncol. 2017; 10(1):146.

PMID: 28774337 PMC: 5543600. DOI: 10.1186/s13045-017-0511-2.

Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers.

Kim B, Jang H, Kim H, Kim J J Cancer. 2017; 8(8):1460-1465.

PMID: 28638461 PMC: 5479252. DOI: 10.7150/jca.18470.

Comparison of endoscopic ultrasonography and magnifying endoscopy for assessment of the invasion depth of shallow gastrointestinal neoplasms: a systematic review and meta-analysis.

Tao Z, Yan C, Zhao H, Tsauo J, Zhang X, Qiu B Surg Endosc. 2017; 31(12):4923-4933.

PMID: 28547665 DOI: 10.1007/s00464-017-5596-8.

References

Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M . Genomic spectra of biliary tract cancer. Nat Genet. 2015; 47(9):1003-10. DOI: 10.1038/ng.3375. View

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Conry R, Curiel D, Strong T, Moore S, Allen K, Barlow D . Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res. 2002; 8(9):2782-7. View

Karlsson M, Marits P, Dahl K, Dagoo T, Enerback S, Thorn M . Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer. Ann Surg Oncol. 2010; 17(7):1747-57. PMC: 2889279. DOI: 10.1245/s10434-010-0920-8. View

Ralph C, Elkord E, Burt D, ODwyer J, Austin E, Stern P . Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res. 2010; 16(5):1662-72. DOI: 10.1158/1078-0432.CCR-09-2870. View

Hanna Jr M, Hoover Jr H, Vermorken J, Harris J, Pinedo H . Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine. 2001; 19(17-19):2576-82. DOI: 10.1016/s0264-410x(00)00485-0. View

Lesterhuis W, de Vries I, Aarntzen E, de Boer A, Scharenborg N, van de Rakt M . A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. Br J Cancer. 2010; 103(9):1415-21. PMC: 2990614. DOI: 10.1038/sj.bjc.6605935. View

Bustin S, Li S, Phillips S, Dorudi S . Expression of HLA class II in colorectal cancer: evidence for enhanced immunogenicity of microsatellite-instability-positive tumours. Tumour Biol. 2001; 22(5):294-8. DOI: 10.1159/000050630. View

Bauer K, Michel S, Reuschenbach M, Nelius N, von Knebel Doeberitz M, Kloor M . Dendritic cell and macrophage infiltration in microsatellite-unstable and microsatellite-stable colorectal cancer. Fam Cancer. 2011; 10(3):557-65. DOI: 10.1007/s10689-011-9449-7. View

10.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

11.

Mazzaferro V, Coppa J, Carrabba M, Rivoltini L, Schiavo M, Regalia E . Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res. 2003; 9(9):3235-45. View

12.

Zhang L, Zhu W, Li J, Yang X, Ren Y, Niu J . Clinical outcome of immunotherapy with dendritic cell vaccine and cytokine-induced killer cell therapy in hepatobiliary and pancreatic cancer. Mol Clin Oncol. 2016; 4(1):129-133. PMC: 4727101. DOI: 10.3892/mco.2015.660. View

13.

Kono K, Takahashi A, Sugai H, Fujii H, Choudhury A, Kiessling R . Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res. 2002; 8(11):3394-400. View

14.

Jung K, Won Y, Kong H, Oh C, Lee D, Lee J . Prediction of cancer incidence and mortality in Korea, 2014. Cancer Res Treat. 2014; 46(2):124-30. PMC: 4022820. DOI: 10.4143/crt.2014.46.2.124. View

15.

Czerniecki B, Koski G, Koldovsky U, Xu S, Cohen P, Mick R . Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 2007; 67(4):1842-52. DOI: 10.1158/0008-5472.CAN-06-4038. View

16.

Postow M, Chesney J, Pavlick A, Robert C, Grossmann K, McDermott D . Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015; 372(21):2006-17. PMC: 5744258. DOI: 10.1056/NEJMoa1414428. View

17.

Llosa N, Cruise M, Tam A, Wicks E, Hechenbleikner E, Taube J . The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2014; 5(1):43-51. PMC: 4293246. DOI: 10.1158/2159-8290.CD-14-0863. View

18.

Testori A, Richards J, Whitman E, Mann G, Lutzky J, Camacho L . Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol. 2008; 26(6):955-62. DOI: 10.1200/JCO.2007.11.9941. View

19.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Nakamori M, Ueda K . Benefits of gene transduction of granulocyte macrophage colony-stimulating factor in cancer vaccine using genetically modified dendritic cells. Int J Oncol. 2007; 31(4):931-9. View

20.

Correale P, Rotundo M, Del Vecchio M, Remondo C, Migali C, Ginanneschi C . Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother. 2010; 33(4):435-41. PMC: 7322625. DOI: 10.1097/CJI.0b013e3181d32f01. View